Target intelligence / Profile preview

Chikungunya virus E1 envelope glycoprotein (E1)

Target
E1
Molecular classification
Viral envelope protein, Class II fusion protein, Glycoprotein
01

Overview

The Chikungunya virus E1 envelope glycoprotein is a class II viral fusion protein essential for the entry of the Chikungunya virus (CHIKV) into host cells. On the mature virion surface, E1 forms a heterodimeric complex with the E2 glycoprotein, which facilitates viral attachment to host receptors. Following endocytosis, the acidic environment of the endosome triggers a conformational change that dissociates the E1-E2 heterodimer and allows E1 to form a fusogenic homotrimer. This process inserts a fusion peptide into the host endosomal membrane, pulling the viral and host membranes together to release the viral nucleocapsid into the cytoplasm. Because of its indispensable role in the viral life cycle, E1 is a primary target for neutralizing antibodies and the development of vaccines and small-molecule fusion inhibitors. Therapeutic strategies often focus on stabilizing the E1-E2 complex or blocking the structural transitions of E1 to prevent infection.

Other names
E1 proteinCHIKV E1Chikungunya virus E1 proteinEnvelope glycoprotein E1Fusion protein E1
02

Mechanism of action

Inhibition of pH-dependent membrane fusion by preventing the conformational rearrangement of E1 from a heterodimer with E2 into a fusogenic homotrimer, thereby blocking viral entry.

03

Biological functions

Viral entryMembrane fusionViral assemblyAttachmentHost cell penetration
04

Disease associations

InfectionChikungunya feverArthritisArthralgia
05

Safety considerations

Viral escape mutations (e.g., E1-A226V mutation)Antibody-dependent enhancement (ADE)Cross-reactivity with other alphavirusesPotential for chronic arthralgia despite treatment
06

Interacting drugs

Ixchiq

3 more in the full profile.

07

Biomarkers

Anti-E1 IgM antibodiesAnti-E1 IgG antibodiesCHIKV RNA viral loadNeutralizing antibody titer (PRNT)

Beyond the preview

Go deeper on Chikungunya virus E1 envelope glycoprotein (E1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chikungunya virus E1 envelope glycoprotein (E1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call